or Try an Advanced Search...

    Technical Analysis for RPRX - Royalty Pharma plc

    Grade Last Price % Change Price Change
    F 27.37 0.37% 0.10
    RPRX closed down 2.19 percent on Friday, May 17, 2024, on 73 percent of normal volume.
    Earnings due: Jun 6
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RPRX trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.37%
    BB Squeeze + Lower Band Touch Range Contraction 0.37%
    Below Lower BB Weakness 0.37%
    Lower Bollinger Band Touch Weakness 0.37%
    200 DMA Resistance Bearish -1.83%
    Fell Below 20 DMA Bearish -1.83%
    Bollinger Band Squeeze Range Contraction -1.83%
    Outside Day Range Expansion -1.83%
    200 DMA Resistance Bearish -2.25%
    Crossed Above 20 DMA Bullish -2.25%
    Older End-of-Day Signals for RPRX ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 1 hour ago
    Rose Above Lower Bollinger Band about 1 hour ago
    Down 2 % 3 days ago
    Down 1 ATR 3 days ago
    60 Minute Opening Range Breakdown 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RPRX Chart by TradingView
    Basic chart:

    Profile

    Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products

    Is RPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Royalty Pharma to Present at Upcoming Investor Conferences
    May 12 Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
    May 11 Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
    May 11 Royalty Pharma: Solid Start Of The Year, Buy Confirmed
    May 9 Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
    May 9 Royalty Pharma reports Q1 results
    May 9 Royalty Pharma Reports First Quarter 2024 Results
    May 9 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
    May 8 Royalty Pharma Q1 2024 Earnings Preview
    May 8 Teva, Medincell succeed in late-stage trial for injectable schizophrenia therapy
    See more RPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 33.6646
    52 Week Low 25.3535
    Average Volume 2,609,769
    200-Day Moving Average 28.14
    50-Day Moving Average 28.71
    20-Day Moving Average 27.88
    10-Day Moving Average 27.90
    Average True Range 0.57
    RSI (14) 38.27
    ADX 14.37
    +DI 13.60
    -DI 24.72
    Chandelier Exit (Long, 3 ATRs) 27.07
    Chandelier Exit (Short, 3 ATRs) 28.71
    Upper Bollinger Bands 28.44
    Lower Bollinger Band 27.33
    Percent B (%b) -0.05
    BandWidth 3.99
    MACD Line -0.22
    MACD Signal Line -0.23
    MACD Histogram 0.0114
    Fundamentals Value
    Market Cap 12.18 Billion
    Num Shares 447 Million
    EPS 0.39
    Price-to-Earnings (P/E) Ratio 69.92
    Price-to-Sales 7.40
    Price-to-Book 2.13
    PEG Ratio 0.09
    Dividend 0.79
    Dividend Yield 2.90%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 28.16
    Resistance 3 (R3) 28.24 28.04 28.01
    Resistance 2 (R2) 28.04 27.81 27.99 27.96
    Resistance 1 (R1) 27.65 27.67 27.55 27.57 27.91
    Pivot Point 27.45 27.45 27.40 27.40 27.45
    Support 1 (S1) 27.06 27.22 26.96 26.98 26.63
    Support 2 (S2) 26.86 27.08 26.81 26.58
    Support 3 (S3) 26.47 26.86 26.53
    Support 4 (S4) 26.39